Longtime biotech investor injects $250M into Palo Alto company a year after IPO By: San Francisco Business Times via Business Journals December 02, 2019 at 09:51 AM EST Kodiak Sciences is in a pivotal trial with its lead drug against a blinding eye disease. Read More >>